Biotech entity
pharma is the sole category represented across all 3 tracked stories. Source depth averages 4.7 original sources per story, versus 3.4 across the same-window beat baseline. Alison Moore is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories.
Last mentioned: Mar 23, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 3 tracked stories. Source depth averages 4.7 original sources per story, versus 3.4 across the same-window beat baseline. Alison Moore is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. Across a 25-day span, the pace is roughly 0.8 stories per week. Their average consequence score of 6 runs below the beat's 6.1 for that window. This profile follows 3 Biotech stories mentioning Boston Scientific across the period from February 27, 2026 to March 23, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 315 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Boston Scientific. Shared-story counts are live from our verified record — not editorial picks.
Lead Plaintiff Deadline
Expected deadline for shareholders to petition the court to serve as lead plaintiff in the case.
Follow-up Disclosure
Secondary announcements highlight the filing and the process for shareholders to join the litigation.
Class Action Announcement
Pomerantz LLP first alerts investors to the class action filing against Boston Scientific.
Pomerantz LLP has initiated a class action lawsuit against Boston Scientific (BSX), alleging potential violations of federal securities laws. The litigation centers on the company's disclosures during a period of significant expansion and product integration, marking a critical legal challenge for the medical device giant.
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
The Australian government is significantly reducing subsidies for high-cost spinal cord stimulators following reports of severe patient injuries and a lack of clinical efficacy. This regulatory shift targets a multi-million dollar sector of the medical device market, forcing manufacturers to justify the high price tags of chronic pain technologies.
Boston Scientific is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
